Affiliation:
1. From the Division of Immunity and Infection, the Cancer Research UK Clinical Trials Unit, and the Department of Haematology, Royal Wolverhampton NHS Trust and Division of Cancer Studies, University of Birmingham, Birmingham, United Kingdom; and the Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom.
Abstract
AbstractWhile investigating 2592 patients enrolled in multicenter myeloma trials, we found light chain–only (LCO) patients had worse median survival times (1.9 years) than patients with IgA and IgG paraproteins (2.3 and 2.5 years, respectively) (P < .001). However, IgA and IgG patients with levels of LC excretion similar to those of LCO patients also had poor survival times because of renal failure, resulting in worse survival during induction therapy and at relapse with no difference in progression-free survival between LCO and IgG patients. LC excretion was higher for λ than for κ types, but there was no difference in survival between the 2 LC types when stratified for level of LC excretion, indicating that care of renal function is vital to improving the survival of any patient with LC excretion. LCO patients were younger (P = .001), had worse performance status (P = .001), and had more lytic lesions (P < .001), perhaps reflecting late and missed diagnoses in younger and older LCO patients, respectively. No differences were observed between IgA and IgG patients in presentation characteristics, response, or survival from disease progression. The worse survival of IgA patients was attributed to shorter progression-free survival (median, 1.2 vs 1.6 years; P < .001), which is important for maintenance therapy.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference35 articles.
1. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78: 21-33.
2. Bladé J, San Miguel JF, Fontanillas M, et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Haematologica. 2001;2: 272-278.
3. Jacobson JL, Hussein MA, Barlogie B, et al. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003;122: 441-450.
4. Sirohi B, Powles R. Multiple myeloma. Lancet. 2004;363: 875-887.
5. Melchers F, Haasner D, Grawunder U, et al. Roles of IgH and L chains and of surrogate H and L chains in the development of cells of the B lymphocyte lineage [review]. Annu Rev Immunol. 1994;12: 209-225.
Cited by
77 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献